DOHERTY, K. (2026). ctDNA Testing Is Poised to Reshape Risk Assessment and Treatment Decision-Making in Bladder Cancer. OncologyLive, 27(5), 18.
Chicago Style (17th ed.) CitationDOHERTY, KYLE. "CtDNA Testing Is Poised to Reshape Risk Assessment and Treatment Decision-Making in Bladder Cancer." OncologyLive 27, no. 5 (2026): 18.
MLA (9th ed.) CitationDOHERTY, KYLE. "CtDNA Testing Is Poised to Reshape Risk Assessment and Treatment Decision-Making in Bladder Cancer." OncologyLive, vol. 27, no. 5, 2026, p. 18.
Warning: These citations may not always be 100% accurate.